‘Dementia link to sudden low blood pressure and dizziness’
October 13, 2024
A phase 3 trial exploring whether the compound LMTX can stop the development of a key hallmark of Alzheimer’s disease has been initiated by pharmaceutical company TauRx Therapies.
The study will involve over 1,500 patients in 20 countries including patients at 16 medical centres in the UK.
100 patients so far have begun the trial, which will investigate whether the compound LMTX could target the buildup of the protein tau on the brain, a process which is thought to play a significant part in the progression of Alzheimer’s.
Alzheimer’s Society comment:
‘We know that tangles of tau, a protein found in the brain, are a hallmark of Alzheimer’s disease and cause the death of brain cells. If we can find a way to stop them building up we could potentially stop Alzheimer’s in its tracks.
It’s a scandal that despite 800,000 people living with dementia in the UK there are more clinical trials for hayfever than some of the most common forms of the condition. This Dementia Awareness Week™ we need people to be shouting from the rooftops for more research into dementia to defeat it once and for all.’
Source Alzheimer’s Society